A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer

Jung Sun Kim, Koung Jin Suh, Dae Won Lee, Go Un Woo, Miso Kim, Se Hyun Kim, Han Suk Ryu, Kyung Hun Lee, Tae Yong Kim, Sae Won Han, So Yeon Park, In Ae Park, Jee Hyun Kim, Seock Ah Im

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Purpose We aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients. Materials and Methods This is a retrospective study performed in two tertiary referral hospitals in Korea. Patients with metastatic breast cancer treated with nab-paclitaxel (Abraxane) between March 2016 and March 2020 were enrolled. Results A total of 102 patients with metastatic breast cancer were included. Patients were heavily pre-treated with a median of four prior lines of chemotherapy (5 lines when including endocrine therapy in hormone-receptor-positive patients), and 66 patients (64.7%) were exposed to taxanes in the metastatic setting. According to St. Gallen molecular subtypes, 36 patients (35.3%) were luminal A, 28 (27.5%) were luminal B, 18 (17.7%) were human epidermal growth factor receptor 2-positive and 20 (19.6%) had triple-negative disease. Fifty patients (49.0%) were treated with a 3-weekly regimen (260 mg/m2 on day 1 every 3 weeks), and 52 (51.0%) were treated with a weekly regimen (100 mg/m2 every week). Objective response rate was 22.9%. After a median follow-up of 22.0 months, median progression-free survival (PFS) was 4.0 months (95% confidence interval [CI], 2.6 to 4.8) and median overall survival was 8.7 months (95% CI, 7.5 to 11.2). Patients treated with weekly regimen had longer PFS compared to 3-weekly regimen (5.5 vs. 2.3 months, p < 0.001). Multivariate analysis revealed the treatment regimen as an independent prognostic factor for PFS. There was no grade 3 or 4 hypersensitivity reaction. Conclusion This real-world data shows that nab-paclitaxel is a reasonable treatment option in heavily pre-treated and/or taxane-exposed metastatic breast cancer patients.

Original languageEnglish
Pages (from-to)488-496
Number of pages9
JournalCancer Research and Treatment
Volume54
Issue number2
DOIs
StatePublished - Apr 2022

Keywords

  • Albumin-bound paclitaxel
  • Breast neoplasms
  • Neoplasm metastasis

Fingerprint

Dive into the research topics of 'A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer'. Together they form a unique fingerprint.

Cite this